Overview

Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Phase II Trial of Hypofractionated Intensity Modulated Radiation Therapy(IMRT) With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor(GM-CSF) for Patients With Newly Diagnosed Glioblastoma Multiforme.

Phase:

Phase 2

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Treatments:

Dacarbazine
Molgramostim
Sargramostim
Temozolomide